New treatment opportunity expected to patients with cold agglutinin disease
[Newsmp] On the 12th, the Ministry of Food and Drug Safety granted approval to Sanofi's Enjaymo (ingredient: sutimlimab) for treating hemolysis in adult patients with cold agglutinin disease.
Enjaymo is indicated for hemolytic therapy in adult patients with autoimmune hemolytic anemia (AIHA), a type of cold agglutinin disease.
Cold agglutinin disease is a rare type of autoimmune hemolytic anemia that causes hemolysis by agglutinating red blood cells at temperatures below normal body temperature.
By binding to complement protein component 1, s subcomponent (C1s), Enjaymo, an immunoglobulin G subclass 4 (IgG4) monoclonal antibody, inhibits the classical complement pathway.
저작권자 © 의약뉴스 무단전재 및 재배포 금지
